DelveInsight's“ Multiple System Atrophy Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Multiple System Atrophy pipeline landscape. It ...

ATH434 improves daily function and reduces brain iron in patients with multiple system atrophy, a rare, fatal ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Alterity Therapeutics’ phase II study of its lead compound ATH434 in multiple system atrophy (MSA) has been featured in an oral presentation at the American Autonomic Society (AAS) 36th International ...

The α-synuclein protein can adopt several different conformations that cause neurodegeneration. Different α-synuclein conformers cause at least three distinct α-synucleinopathies: multiple system ...

Shares in Theravance Biopharma (NASDAQ: TBPH) surged by more than 21% as of noontime ET today. The move comes as the market ...

An update from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics presented promising data on ATH434 at the 36th ...

Parkinson’s disease (PD) remains one of the most challenging neurodegenerative disorders to diagnose and monitor.

As of November 12, 2025, ProMIS has fully enrolled Cohorts 1 and 2 and is well into Cohort 3, with complete enrollment expected before the end of the year. PMN310 continues to demonstrate a favorable ...

The software industry is undergoing a profound transformation, driven by advances in AI. Alexey Astakhov, Vice President of ...

Women who have had traumatic birth experiences at Royal Darwin Hospital have gathered to share their stories and call for urgent action from the territory and federal governments.

When it comes to China and anyone else, Luxon plays ball with whoever will catch it. With full of fake smiles, he totters off ...